Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Univariate and multivariate Cox models of OS

From: Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

  Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.042 0.999–1.086 0.054 1.019 0.962–1.079 0.522
BMI 1.013 0.943–1.088 0.730    
HR status 2.019 0.942–4.328 0.071 2.104 0.978–4.529 0.057
Menopausal status 2.133 1.081–4.210 0.029 1.768 0.670–4.665 0.250
cN status 3.921 1.624–9.471 0.002 4.060 1.672–9.859 0.002
cT status 1.680 0.857–3.295 0.131 1.1516 0.763–3.011 0.235
Zoledronic acid 0.448 0.218–0.919 0.029 0.468 0.226–0.967 0.040
  1. Bold values indicate that P < 0.05OS overall survival, HR hazard ratio, CI confidence interval, BMI body mass index
  2. the italicized data have a significance of > 0.05